-
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current ...Phase
Interventional
-
Movement Disorder Genomic Study
With the present study we aim to perform integrated genomic analysis and study on subject-specific cellular models in order to identify genetic causes of rare ...Phase N/A
Non-Interventional
Accepts Healthy Volunteer
-
Genetic Screening Outcomes in Movement Disorders
Understanding the correlation between genetic mutations and causative pathogenic mechanisms and phenotypes in Movement Disorders may significantly contribute to implementing therapeutic approaches for these conditions ...Phase N/A Non-Interventional
-
Psoriatic Response and Onset: Genes Radiology Environment Skin and Synovium)
This is a longitudinal, observational cohort study to aimed to understand the clinical and biologic underpinnings of psoriasis and psoriatic arthritis development and severity. To ...Phase N/A Non-Interventional
Accepts Healthy Volunteer
-
AGCT1532: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Bleomycin, Etoposide, Cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). Cure rates are ...Phase
Interventional
-
Registry for SETD2 Neurodevelopmental Disorder
This study involves the collection of data from individuals who have SETD2-neurodevelopmental disorders. By collecting clinical information and administering surveys to affected individuals or their ...Phase N/A Non-Interventional
Accepts Healthy Volunteer
-
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
This Phase III, randomized, double-blind (DB), placebo-controlled, multicenter study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as ...Phase
Interventional
-
Effects of sleep among infants and toddlers on their neurodevelopmental outcomes
This study will examine the effects of infant and toddler sleep patterns among preterm and full-term infants on their neurodevelopmental outcomes following discharge from the ...Phase N/A Non-Interventional
Accepts Healthy Volunteer
-
Primary Ciliary Dyskinesia Foundation (PCDF) Registry: A longitudinal study of patients with primary ciliary dyskinesia
PCD Foundation (PCDF) Registry: A longitudinal study of patients with primary ciliary dyskinesia Establishment of a registry will allow for an improved understanding of demographics ...Phase N/A Non-Interventional
-
Parkinson s Foundation PD GENEration Genetic Registry
The Parkinson’s Foundation PDGENEration Genetic Registry study is a prospective registry study of people who are clinically diagnosed with PD. The participants will consist ...Phase N/A Non-Interventional
